AU2001292993A1 - Compositions for reducing side effects in chemotherapeutic treatments - Google Patents

Compositions for reducing side effects in chemotherapeutic treatments

Info

Publication number: AU2001292993A1
Authority: AU; Australia
Prior art keywords: compositions; side effects; reducing side; chemotherapeutic treatments; chemotherapeutic
Prior art date: 2000-09-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001292993A

Inventor

Anatole Klyosov

David Platt

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pro Pharmaceuticals Inc

Original Assignee

Pro Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-25

Filing date

2001-09-24

Publication date

2002-04-08

2001-09-24 Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc

2002-04-08 Publication of AU2001292993A1 publication Critical patent/AU2001292993A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2001292993A 2000-09-25 2001-09-24 Compositions for reducing side effects in chemotherapeutic treatments Abandoned AU2001292993A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23514100P	2000-09-25	2000-09-25
US60/235,141		2000-09-25
PCT/US2001/029754 WO2002026262A2 (en)	2000-09-25	2001-09-24	Compositions for reducing side effects in chemotherapeutic treatments

Publications (1)

Publication Number	Publication Date
AU2001292993A1 true AU2001292993A1 (en)	2002-04-08

Family

ID=22884262

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001292993A Abandoned AU2001292993A1 (en)	2000-09-25	2001-09-24	Compositions for reducing side effects in chemotherapeutic treatments

Country Status (4)

Country	Link
US (2)	US6642205B2 (en)
EP (1)	EP1363673A2 (en)
AU (1)	AU2001292993A1 (en)
WO (1)	WO2002026262A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040100835A (en)	2001-02-15	2004-12-02	킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨	Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6680306B2 (en)	2001-06-21	2004-01-20	Glycogenesys, Inc.	Method for enhancing the effectiveness of cancer therapies
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
CN1838942A (en) *	2003-07-11	2006-09-27	普罗医药公司	Compositions and methods for hydrophobic drug delivery
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (en)	2005-02-04	2006-08-10	Grünenthal GmbH	Break-resistant dosage forms with sustained release
DE10361596A1 (en)	2003-12-24	2005-09-29	Grünenthal GmbH	Process for producing an anti-abuse dosage form
DE102004032051A1 (en)	2004-07-01	2006-01-19	Grünenthal GmbH	Process for the preparation of a secured against misuse, solid dosage form
DE10336400A1 (en)	2003-08-06	2005-03-24	Grünenthal GmbH	Anti-abuse dosage form
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1718146A2 (en) *	2004-02-13	2006-11-08	Pro-Pharmaceuticals, Inc.	Compositions and methods used to treat acne and candida
DE102004032049A1 (en)	2004-07-01	2006-01-19	Grünenthal GmbH	Anti-abuse, oral dosage form
EP1773128A2 (en) *	2004-08-02	2007-04-18	Pro-Pharmaceuticals, Inc.	Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
DE102005005449A1 (en)	2005-02-04	2006-08-10	Grünenthal GmbH	Process for producing an anti-abuse dosage form
WO2008011216A2 (en)	2006-05-16	2008-01-24	Pro-Pharmaceuticals, Inc.	Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
AU2009207796B2 (en)	2008-01-25	2014-03-27	Grunenthal Gmbh	Pharmaceutical dosage form
HRP20161307T1 (en)	2008-05-09	2016-12-02	Grünenthal GmbH	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PE20120631A1 (en)	2009-07-22	2012-06-06	Gruenenthal Chemie	HANDLING RESISTANT DOSAGE FORM FOR OPIOIDS SENSITIVE TO OXIDATION
CA2765971C (en)	2009-07-22	2017-08-22	Gruenenthal Gmbh	Hot-melt extruded controlled release dosage form
AR082862A1 (en)	2010-09-02	2013-01-16	Gruenenthal Gmbh	ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER
PL2611426T3 (en)	2010-09-02	2014-09-30	Gruenenthal Gmbh	Tamper resistant dosage form comprising inorganic salt
KR20140053159A (en)	2011-07-29	2014-05-07	그뤼넨탈 게엠베하	Tamper-resistant tablet providing immediate drug release
HRP20171458T1 (en)	2011-07-29	2017-11-17	Grünenthal GmbH	Tamper-resistant tablet providing immediate drug release
JP6117249B2 (en)	2012-02-28	2017-04-19	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
PT2838512T (en)	2012-04-18	2018-11-09	Gruenenthal Gmbh	Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9339515B2 (en)	2013-02-20	2016-05-17	Galectin Therapeutics, Inc.	Method for treatment of pulmonary fibrosis
EP3613468A1 (en)	2013-05-02	2020-02-26	Glykos Finland Oy	Glycoprotein-toxic payload conjugates
BR112015026549A2 (en)	2013-05-29	2017-07-25	Gruenenthal Gmbh	tamper-proof dosage form containing one or more particles
US9737490B2 (en)	2013-05-29	2017-08-22	Grünenthal GmbH	Tamper resistant dosage form with bimodal release profile
EA032465B1 (en)	2013-07-12	2019-05-31	Грюненталь Гмбх	Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
EP3142646A1 (en)	2014-05-12	2017-03-22	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en)	2014-05-26	2015-12-03	Grünenthal GmbH	Multiparticles safeguarded against ethanolic dose-dumping
JP5924795B2 (en)	2014-06-13	2016-05-25	テンボロンオイ	Complex
AU2015282627B2 (en)	2014-06-30	2020-04-02	Glykos Finland Oy	Saccharide derivative of a toxic payload and antibody conjugates thereof
HK1246173A1 (en)	2015-04-24	2018-09-07	Grünenthal GmbH	Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017042325A1 (en)	2015-09-10	2017-03-16	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2025092728A1 (en) *	2023-10-30	2025-05-08	上海皓元生物医药科技有限公司	Intermediate of pnu-159682, and preparation method therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350836A (en) *	1989-10-12	1994-09-27	Ohio University	Growth hormone antagonists
US5639737A (en) *	1991-11-04	1997-06-17	Co Enzyme Technology Ltd.	Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
DE4236237A1 (en) *	1992-10-27	1994-04-28	Behringwerke Ag	Prodrugs, their preparation and use as medicines
DE19524515A1 (en) *	1995-07-05	1997-01-09	Deutsches Krebsforsch	Saccharide conjugates

2001
- 2001-09-24 AU AU2001292993A patent/AU2001292993A1/en not_active Abandoned
- 2001-09-24 EP EP01973411A patent/EP1363673A2/en not_active Withdrawn
- 2001-09-24 US US09/961,681 patent/US6642205B2/en not_active Expired - Lifetime
- 2001-09-24 WO PCT/US2001/029754 patent/WO2002026262A2/en not_active Ceased
2003
- 2003-06-24 US US10/354,750 patent/US20030229028A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1363673A2 (en)	2003-11-26
US20020068077A1 (en)	2002-06-06
WO2002026262A9 (en)	2003-03-20
US6642205B2 (en)	2003-11-04
WO2002026262A3 (en)	2003-07-10
WO2002026262A2 (en)	2002-04-04
US20030229028A1 (en)	2003-12-11

Publication	Publication Date	Title
AU2001292993A1 (en)	2002-04-08	Compositions for reducing side effects in chemotherapeutic treatments
AU2778801A (en)	2001-07-24	Antisense compositions and methods
AU2001293309A1 (en)	2002-04-02	Crosstalk reduction in constrained wiring assemblies
AU2001267878A1 (en)	2002-01-14	Hypoglycemics
AU2001241098A1 (en)	2001-10-08	Composition
AUPR551901A0 (en)	2001-07-12	Improvements in packaging
AU2002236455A1 (en)	2002-05-27	Synergistic ecta compositions
AU2002301354A1 (en)	2003-06-12	Improvements in Transmissometers
AU2002301358A1 (en)	2003-06-12	Improvements in Transmissometers
AUPQ634300A0 (en)	2000-04-15	Synergistic formulations
AU2001272655A1 (en)	2002-02-05	Improvements in valves
AUPQ644900A0 (en)	2000-04-20	Preserving compositions
AU2001275201A1 (en)	2001-12-11	Acne-treating composition
AU2001287852A1 (en)	2002-03-26	Composition
AU2001231107A1 (en)	2001-11-12	Improved lactational
AU2002211741A1 (en)	2002-04-22	Surface modifying composition
AU2001295991A1 (en)	2002-05-06	Compositions for improving lipids in blood
AU2001287732A1 (en)	2002-04-08	Copolycarbonate-based composition
AU2001262163A1 (en)	2002-04-22	Composition
AU2387201A (en)	2001-07-24	Improvements in transceivers
AU2002238794A1 (en)	2002-06-03	Methods and compositions involved in groucho-mediated differentiation
AU2002221748A1 (en)	2002-07-01	Stain treatment composition
AU7621800A (en)	2001-04-30	Methods and compositions for reducing sympathomimetic-induced side effects
AU4899901A (en)	2001-12-11	Leading in roller box (variants)
AUPQ795300A0 (en)	2000-06-29	Improvements in elevators